Ortin Laboratories (BOM:539287) 3-Year Revenue Growth Rate : -68.70% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Ortin Laboratories 3-Year Revenue Growth Rate?

Ortin Laboratories's Revenue per Share for the three months ended in Dec. 2023 was ₹0.17.

During the past 12 months, Ortin Laboratories's average Revenue per Share Growth Rate was -50.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -68.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -51.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Ortin Laboratories was 60.40% per year. The lowest was -68.70% per year. And the median was -17.00% per year.

Competitive Comparison of Ortin Laboratories's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Laboratories's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ortin Laboratories's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ortin Laboratories's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ortin Laboratories's 3-Year Revenue Growth Rate falls into.

Ortin Laboratories 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Ortin Laboratories (BOM:539287) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Ortin Laboratories 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ortin Laboratories's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ortin Laboratories (BOM:539287) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ortin Laboratories Ltd (BOM:539287) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

ORTINLAB:India

Address

Street no. 3, D. No. 1-8-B4, Ground Floor,Block-4, F3 HIG, Baghlingampally, Hyderabad, TG, IND, 500 044

Website

https://www.ortinlabsindia.com

Ortin Laboratories Ltd is an India based engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its APIs Intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zudavudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others.It earns key revenue from domestic sales.

Ortin Laboratories (BOM:539287) Headlines

No Headlines